# Protalix BioTherapeutics, Inc.: overview PLX · NYSE · CIK 1006281 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/plx.md) · [Financials](/companies/plx/financials.md) · [Filings](/companies/plx/filings.md) · [Insiders](/companies/plx/insiders.md) Latest reported revenue: [$19.9m](/filings/0001104659-26-094444.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:Revenues, accession 0001104659-26-094444). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [18.0](/filings/0001104659-25-110824.md) | [18.2 d](/filings/0001104659-26-029858.md) | [10.1](/filings/0001104659-26-059756.md) | [15.7](/filings/0001104659-26-094444.md) | [17.9](/filings/0001104659-25-110824.md) | [9.1 d](/filings/0001104659-26-029858.md) | [33.8](/filings/0001104659-26-059756.md) | [19.9](/filings/0001104659-26-094444.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [22.2%](/filings/0001104659-25-110824.md) | [39.6% d](/filings/0001104659-26-029858.md) | [(41.0%)](/filings/0001104659-26-059756.md) | [7.5%](/filings/0001104659-26-094444.md) | [11.9%](/filings/0001104659-25-110824.md) | [(51.1%) d](/filings/0001104659-26-029858.md) | [62.7%](/filings/0001104659-26-059756.md) | [23.5%](/filings/0001104659-26-094444.md) | | Net margin | % | [18.0%](/filings/0001104659-25-110824.md) | [35.6% d](/filings/0001104659-26-029858.md) | [(35.8%)](/filings/0001104659-26-059756.md) | [1.0%](/filings/0001104659-26-094444.md) | [13.2%](/filings/0001104659-25-110824.md) | [(60.3%) d](/filings/0001104659-26-029858.md) | [54.3%](/filings/0001104659-26-059756.md) | [19.0%](/filings/0001104659-26-094444.md) | | Diluted EPS | $ per share | [0.03](/filings/0001104659-25-110824.md) | not reported | [(0.05)](/filings/0001104659-26-059756.md) | [0.00](/filings/0001104659-26-094444.md) | [0.03](/filings/0001104659-25-110824.md) | not reported | [0.22](/filings/0001104659-26-059756.md) | [0.05](/filings/0001104659-26-094444.md) | | Free cash flow | $m | [4.0 d](/filings/0001104659-25-110824.md) | [3.6 d](/filings/0001104659-26-029858.md) | [(5.4)](/filings/0001104659-26-059756.md) | [(5.7) d](/filings/0001104659-26-094444.md) | [(4.2) d](/filings/0001104659-25-110824.md) | [1.6 d](/filings/0001104659-26-029858.md) | [21.3](/filings/0001104659-26-059756.md) | [(11.0) d](/filings/0001104659-26-094444.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [38.4](/filings/0001558370-24-003161.md) | [47.6](/filings/0001558370-25-003039.md) | [65.5](/filings/0001104659-26-029858.md) | [53.4](/filings/0001104659-26-029858.md) | [52.7](/filings/0001104659-26-029858.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(53.4%)](/filings/0001558370-24-003161.md) | [(27.3%)](/filings/0001558370-25-003039.md) | [16.0%](/filings/0001104659-26-029858.md) | [7.3%](/filings/0001104659-26-029858.md) | [(10.4%)](/filings/0001104659-26-029858.md) | | Net margin | % | [(71.9%)](/filings/0001558370-24-003161.md) | [(31.3%)](/filings/0001558370-25-003039.md) | [12.7%](/filings/0001104659-26-029858.md) | [5.5%](/filings/0001104659-26-029858.md) | [(12.5%)](/filings/0001104659-26-029858.md) | | Diluted EPS | $ per share | [(0.62)](/filings/0001558370-24-003161.md) | [(0.31)](/filings/0001558370-25-003039.md) | [0.09](/filings/0001104659-26-029858.md) | [0.04](/filings/0001104659-26-029858.md) | [(0.08)](/filings/0001104659-26-029858.md) | | Free cash flow | $m | [(11.7)](/filings/0001558370-24-003161.md) | [(25.6)](/filings/0001558370-25-003039.md) | [(2.5)](/filings/0001104659-26-029858.md) | [7.4](/filings/0001104659-26-029858.md) | [(13.6)](/filings/0001104659-26-029858.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/plx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $9.4m | 4,046,650 | | Added +429,688 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $2.6m | 1,096,000 | | Reduced −128,800 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $2.3m | 983,582 | | Added +10,767 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $2.3m | 979,995 | | Added +114,697 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $2.1m | 922,340 | | Added +36,892 | | [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.2m | 510,639 | | Added +78,154 | | [Stratos Wealth Partners, LTD.](/funds/1612865.md) | 2026-06-30 | $1.2m | 500,000 | | Unchanged | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $1.1m | 493,424 | | Added +196,581 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $1.1m | 475,922 | | Added +224,577 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $1.1m | 452,757 | | New +452,757 | ## Recent filings [All 750 filings](/companies/plx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-12 | 11:09 ET | [10-Q](/filings/0001104659-26-094444.md) | Quarterly report, period 2026-06-30 | 0001104659-26-094444 | | 2026-08-12 | 10:59 ET | [8-K](/filings/0001104659-26-094433.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-094433 | | 2026-06-25 | 20:30 ET | [8-K](/filings/0001104659-26-077790.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-077790 | | 2026-05-21 | 11:03 ET | [8-K](/filings/0001104659-26-064850.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-064850 | | 2026-05-13 | 11:06 ET | [10-Q](/filings/0001104659-26-059756.md) | Quarterly report, period 2026-03-31 | 0001104659-26-059756 | | 2026-05-13 | 10:57 ET | [8-K](/filings/0001104659-26-059749.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-059749 | | 2026-04-30 | 20:30 ET | [DEF 14A](/filings/0001104659-26-053016.md) | Proxy statement, period 2026-06-25 | 0001104659-26-053016 | | 2026-03-18 | 11:12 ET | [10-K](/filings/0001104659-26-029858.md) | Annual report, period 2025-12-31 | 0001104659-26-029858 | | 2026-03-18 | 10:56 ET | [8-K](/filings/0001104659-26-029846.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-029846 | | 2026-03-09 | 11:51 ET | [8-K](/filings/0001104659-26-024975.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-024975 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-029858.md), filed Mar 18, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/85d8640a-419a-460e-abe4-7b5ebe1a4a20) ## About the filer - CIK: 1006281 - Tickers: PLX - Exchange: NYSE - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.